EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chrysin sensitizes glioblastoma cells and spheroids to temozolomide treatment by reducing EMT and stemness phenotypes, as well as targeting multidrug resistance proteins

Yunus Aksüt, Aslıhan Şengelen, Dudu Melek Gürsoy, İrem Öğütcü, Özge Kuvet, Murat Pekmez

Frontiers in Pharmacology · 02.09.2025 · 16

DOI: 10.3389/fphar.2025.1643186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.09.2025. Verfasst von Yunus Aksüt und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Genetics, Faculty of Science, Istanbul University, Istanbul, Türkiye. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bilimsel Araştirma Projeleri Birimi, Istanbul Üniversitesi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma (GB, grade-IV astrocytoma) is a highly aggressive brain tumor often resistant to treatment with temozolomide (TMZ) due to multidrug resistance (MDR). Researchers are investigating natural compounds, such as chrysin (CHR), with anti-cancer properties; however, its ability to overcome drug resistance remains unclear. This study aimed to evaluate the possible synergistic effects of CHR and TMZ on glioblastoma cells in 2D- and 3D-culture models.

Methods

Based on cytotoxicity (MTT test) and synergism analysis, U-87MG cells were treated with CHR (25 μM) and TMZ (250 μM), individually or combined, for 48 hours. Clonogenicity, migration, and invasion were assessed. Fluorescence staining was used to assess MtMP collapse, ER stress, autophagy, apoptosis, and target protein localization. Protein level alterations were measured using Western blotting, and network pharmacology was used to identify shared molecular targets. Antitumor effects were also assessed in 3D-tumor spheroids (mimics in vivo tumors), through viability and growth analyses.

Results

The combined treatment was more effective in reducing cell proliferation than either agent alone, in a dose- and time-dependent manner. CHR increased TMZ cytotoxicity by promoting mitochondrial dysfunction, ER stress, autophagy, and apoptosis, and further decreased motility, clonogenicity, EMT status, and stem-like traits. Co-treatment also suppressed the TMZ-induced upregulation and nuclear translocation of P-glycoprotein (identified as a key CHR target through network pharmacology analysis) and NF-κB-p65, as well as reduced the expression of stress proteins (Hsp60, Hsp70, Hsp90) and MRP1. In 3D spheroid models, co-treatments significantly impaired growth and viability.

Conclusion

These findings suggest that CHR may be a promising adjuvant to TMZ therapy, providing novel insights into overcoming chemoresistance in GB treatment.

Schlagwörter

Stichwörter der Autor:innen

cellular responsechrysin (CHR)drug synergismglioblastoma cells and spheroidsmultidrug resistance proteinstemozolomide (TMZ)

Autor:innen und Institutionen

  • Department of Molecular Biology and Genetics, Faculty of Science, Istanbul University, Istanbul, Türkiye.
  • Department of Molecular Biology and Genetics, Basic Medical Sciences, School of Medicine, Koç University, Istanbul, Türkiye.
  • Department of Molecular Biology and Genetics, Institute of Graduate Studies in Sciences, Istanbul University, Istanbul, Türkiye.

Förderung

  • Bilimsel Araştirma Projeleri Birimi, Istanbul Üniversitesi

Zitieren

APA

Aksüt, Y., Şengelen, A., Gürsoy, D. M., Öğütcü, İ., Kuvet, Ö., & Pekmez, M. (2025). Chrysin sensitizes glioblastoma cells and spheroids to temozolomide treatment by reducing EMT and stemness phenotypes, as well as targeting multidrug resistance proteins. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1643186

Vancouver

Aksüt Y, Şengelen A, Gürsoy DM, Öğütcü İ, Kuvet Ö, Pekmez M. Chrysin sensitizes glioblastoma cells and spheroids to temozolomide treatment by reducing EMT and stemness phenotypes, as well as targeting multidrug resistance proteins. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1643186

BibTeX
@article{Akst2025,
  author = {Aksüt, Yunus and Şengelen, Aslıhan and Gürsoy, Dudu Melek and Öğütcü, İrem and Kuvet, Özge and Pekmez, Murat},
  title = {Chrysin sensitizes glioblastoma cells and spheroids to temozolomide treatment by reducing EMT and stemness phenotypes, as well as targeting multidrug resistance proteins},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1643186}
}
Kostenlos starten →